{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:22:11Z","timestamp":1775060531103,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To observe and compare the efficacy of 2% ganciclovir eye drops in the treatment of Posner-Schlossman Syndrome relapses with\/without cytomegalovirus intraocular reactivation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective cohort study enrolling 101 patients diagnosed unilateral Posner-Schlossman Syndrome in Eye &amp;amp; ENT hospital, Fudan University, Shanghai, China. Thorough ophthalmic examinations were given. Aqueous humor sample was collected from the attacked eye of each patient and all pathogen immunoglobulins tests were performed. All patients were treated with appropriate corticosteroids and intraocular pressure-lowering drugs. 2% ganciclovir eye drops were given to patients whose cytomegalovirus antibody aqueous humor\/serum correction ratio &amp;gt;0. Patients were followed up for 2 months. Ocular manifestations and cumulative drug dose were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A cytomegalovirus ratio &amp;gt;0.40 was considered cytomegalovirus reactivation. The reactivation group (<jats:italic>N<\/jats:italic> = 46) had significantly higher percent of iris depigmentation (78.26%, <jats:italic>P<\/jats:italic> &amp;lt; 0.05) and endothelial cell loss rate (19.46%, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) than the latent group (<jats:italic>N<\/jats:italic> = 55, 58.18% and 10.86%, respectively). The cumulative treatment time and 2% ganciclovir doses were 6.50 \u00b1 4.67 weeks and 181.70 \u00b1 130.95 drops for the reactivation group; 5.95 \u00b1 4.11 weeks and 161.89 \u00b1 110.66 drops for the latent group (<jats:italic>P<\/jats:italic> &amp;gt; 0.05). The median cumulative 2% ganciclovir estimated for inflammation control were 252.00 \u00b1 50.71 and 224.00 \u00b1 32.45 drops for the reactivation and latent group. The residual rate of uncontrolled cases was 0.19 \u00b1 0.15 and 0.00, respectively (<jats:italic>P<\/jats:italic> &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A treatment course of 8\u20139 weeks' 2% ganciclovir is recommended to relapses both with and without cytomegalovirus intraocular reactivation. Preventive ganciclovir application may benefit patients with historical cytomegalovirus infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:ext-link>www.chictr.org.cn<\/jats:ext-link>, identifier: ChiCTR1900022340, Date: 2019\/04\/06.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.848820","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T08:26:42Z","timestamp":1646814402000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["2% Ganciclovir Eye Drops Control Posner-Schlossman Syndrome Relapses With\/Without Cytomegalovirus Intraocular Reactivation"],"prefix":"10.3389","volume":"9","author":[{"given":"Qilian","family":"Sheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyi","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangmei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e18123","DOI":"10.1097\/MD.0000000000018123","article-title":"The characteristics of Posner-Schlossman syndrome: a comparison in the surgical outcome between cytomegalovirus-positive and cytomegalovirus-negative patients","volume":"98","author":"Murata","year":"2019","journal-title":"Medicine."},{"key":"B2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.survophthal.2016.12.005","article-title":"Posner-Schlossman syndrome","volume":"62","author":"Megaw","year":"2017","journal-title":"Surv Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ceo.13417","article-title":"Demystifying viral anterior uveitis: a review","volume":"47","author":"Chan","year":"2019","journal-title":"Clin Exp Ophthalmol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajo.2007.12.015","article-title":"Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients","volume":"145","author":"Chee","year":"2008","journal-title":"Am J Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.ajo.2008.09.001","article-title":"Presumed fuchs heterochromic iridocyclitis and Posner-Schlossman syndrome: comparison of cytomegalovirus-positive and negative eyes","volume":"146","author":"Chee","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s10792-014-9928-6","article-title":"Posner-Schlossman syndrome associated with cytomegalovirus infection: a case series from a non-endemic area","volume":"34","author":"Hedayatfar","year":"2014","journal-title":"Int Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/sj.eye.6701757","article-title":"Cytomegalovirus in aetiology of Posner-Schlossman syndrome: evidence from quantitative polymerase chain reaction","volume":"19","author":"Teoh","year":"2005","journal-title":"Eye."},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/BF00136737","article-title":"Possible role of cytomegalovirus infection in the etiology of the Posner-Schlossmann syndrome","volume":"11","author":"Bloch-Michel","year":"1987","journal-title":"Int Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/09273948.2017.1394471","article-title":"Clinical features of CMV-associated anterior uveitis","volume":"26","author":"Chan","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jcv.2007.11.009","article-title":"HCMV microinfections in inflammatory diseases and cancer","volume":"41","author":"Soderberg-Naucler","year":"2008","journal-title":"J Clin Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2147\/OPTH.S30476","article-title":"Long-term results of oral valganciclovir for treatment of anterior segment inflammation secondary to cytomegalovirus infection","volume":"6","author":"Wong","year":"2012","journal-title":"Clin Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12348-016-0078-z","article-title":"Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis","volume":"6","author":"Wong","year":"2016","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/bjo.2009.167767","article-title":"Cytomegalovirus anterior uveitis: outcome of treatment","volume":"94","author":"Chee","year":"2010","journal-title":"Br J Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00417-009-1195-2","article-title":"Intravitreal loading injection of ganciclovir with or without adjunctive oral valganciclovir for cytomegalovirus anterior uveitis","volume":"248","author":"Hwang","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.ajo.2014.08.007","article-title":"Clinical outcomes in cytomegalovirus-positive Posner-Schlossman syndrome patients treated with topical ganciclovir therapy","volume":"158","author":"Su","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e000061","DOI":"10.1136\/bmjophth-2016-000061","article-title":"Efficacy and safety of an extemporaneous pre-paration of 2% ganciclovir eye drops in CMV anterior uveitis","volume":"2","author":"Keorochana","year":"2017","journal-title":"BMJ Open Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3760\/cma.j.issn.0412-4081.2017.02.007","article-title":"Determination of cytomegalovirus IgG synthesis by the albumin correction in the aqueous humor of posner-schlossmann syndrome","volume":"53","author":"Wang","year":"2017","journal-title":"Zhonghua Yan Ke Za Zhi."},{"key":"B18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3760\/cma.j.issn.0412-4081.2018.11.007","article-title":"Effect of 2% ganciclovir eye drops on cytomegalovirus positive Posner-Schlossman syndrome","volume":"54","author":"Zhai","year":"2018","journal-title":"Zhonghua Yan Ke Za Zhi."},{"key":"B19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.survophthal.2020.01.002","article-title":"Steroid-induced glaucoma: epidemiology, pathophysiology, and clinical management","volume":"65","author":"Roberti","year":"2020","journal-title":"Surv Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0161-6420(02)00961-2","article-title":"Cytomegalovirus as a cause of anterior uveitis with sectoral iris atrophy","volume":"109","author":"Markomichelakis","year":"2002","journal-title":"Ophthalmology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/ICU.0000000000000521","article-title":"Ocular manifestations of cytomegalovirus in immunocompetent hosts","volume":"29","author":"Joye","year":"2018","journal-title":"Curr Opin Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/bjophthalmol-2013-304625","article-title":"Clinical features and management of cytomegalovirus corneal endotheliitis: analysis of 106 cases from the Japan corneal endotheliitis study","volume":"99","author":"Koizumi","year":"2015","journal-title":"Br J Ophthalmol."},{"key":"B23","first-page":"377","article-title":"Experimental corneal endotheliitis in rabbit","volume":"41","author":"Zheng","year":"2000","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/eye.2008.239","article-title":"Keratic precipitate morphology in uveitic syndromes including Behcet's disease as evaluated with in vivo confocal microscopy","volume":"23","author":"Mocan","year":"2009","journal-title":"Eye."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1001\/archopht.122.12.1773","article-title":"In vivo confocal microscopy of keratic precipitates","volume":"122","author":"Wertheim","year":"2004","journal-title":"Arch Ophthalmol."},{"key":"B26","first-page":"486","article-title":"Studies of ocular murine cytomegalovirus infection","volume":"26","author":"Hayashi","year":"1985","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.ophtha.2009.02.019","article-title":"Bilateral acute depigmentation of the iris: report of 26 new cases and 4-year follow-up of two patients","volume":"116","author":"Tugal-Tutkun","year":"2009","journal-title":"Ophthalmology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1007040","DOI":"10.1371\/journal.ppat.1007040","article-title":"Cytomegalovirus establishes a latent reservoir and triggers long-lasting inflammation in the eye","volume":"14","author":"Voigt","year":"2018","journal-title":"PLoS Pathog."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.848820\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T08:26:47Z","timestamp":1646814407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.848820\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":28,"alternative-id":["10.3389\/fmed.2022.848820"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.848820","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"article-number":"848820"}}